OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and mortality, is only detected after the onset of clinical symptoms.  Earlier diagnosis may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers.  Clinical and economic benefits may result from appropriate detection and management of subclinical cases, and from averting costs associated with incorrect diagnoses.  We evaluated the financial impact of the novel test versus standard care from a German health care payer perspective. METHODS: We developed a decision-analytic model of the clinical and economic impact resulting from improved sensitivity and specificity of the new test over current diagnostic practice.  Acute management and follow-up costs were associated with true positive, true negative, false positive, and false negative diagnoses.  The base-case analysis assumed that, of all pregnant women, 10% present with risk factors while 90% do not.  The CHF 52 (€-equivalent) test was assumed to be administered after 20 weeks of gestation.  True positive and false negative patients were assumed to enter one of four health states:  mild preeclampsia; severe preeclampsia; eclampsia; or death.  Data pertaining to treatment practices, health care resource utilization, incidence, costs, and funding for detection and management of preeclampsia in Germany were obtained through interviews with clinicians, laboratory managers, and healthcare payers in Germany.  Additional data were obtained from published literature and public databases.  RESULTS: Model results suggest that when used for screening, the novel test would reduce false negative diagnoses of preeclampsia by 67% and false positives by 71%.  Costs per patient are estimated to be €941 with the novel test and €1578 with standard practice, saving an estimated €637 per patient given the novel test. CONCLUSIONS: This test has the potential to improve detection and management of preeclampsia translating into substantial cost savings for German health care payers.